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Background. Early initiation of highly active antiretroviral therapy (HAART) decreases human immunodeficiency virus- (HIV-)
related complications, restores patients’ immunity, decreases viral load, and substantially improves quality of life. However,
antiretroviral treatment failure considerably impedes the merits of HAART. Objective. This study is aimed at determining the
prevalence of immunologic and clinical antiretroviral treatment failure. Methods. A cross-sectional study design using clinical
and immunologic treatment failure definition was used to conduct the study. Sociodemographic characteristics and clinical
features of patients were retrieved from patients’ medical registry between the years 2009 and 2015. All patients who fulfilled the
inclusion criteria in the study period were studied. Predictors of treatment failure were identified using Kaplan-Meier curves and
multivariable Cox regression analysis. Data analysis was done using SPSS version 21 software, and the level of statistical
significance was declared at a p value < 0.05. Results. A total of 770 were studied. The prevalence of treatment failure was
4.5%. The AZT-based regimen (AHR = 16:95, 95% CI: 3.02-95.1, p = 0:001), baseline CD4 count ≥ 301 (AHR = 0:199, 95%
CI: 0.05-0.76, p = 0:018), and bedridden during HAART initiation (AHR = 0:131, 95% CI: 0.029-0.596, p = 0:009) were the
predictors of treatment failure. Conclusion. The prevalence of treatment failure was lower with the risk being higher among
patients on the AZT-based regimen. On the other hand, the risk of treatment failure was lower among patients who started
HAART at baseline CD4 count ≥ 301 and patients who were bedridden during HAART initiation. We recommend further
prospective, multicenter cohort studies to be conducted to precisely detect the prevalence of treatment failure using viral load
determination in the whole country.
1. Introduction
Human immunodeficiency virus (HIV)/acquired immune
disease is a debilitating disease that resulted in modern global
crisis. The disease is not curable, and it has no medication
that can cure yet [1]. Globally, there was a total estimate of
36.9 million people living with HIV in 2017 while about
21.7 million people were receiving antiretroviral therapy
(ART). In Ethiopia, from 610,000 people who lived with
HIV, 437,000 people were receiving ARTmaking ART cover-
age 71% in 2017 [2]. In developed countries, antiretroviral
effectiveness has been successfully demonstrated [3]. How-
ever, there are few studies conducted in developing countries
with scarce resources declaring effectiveness of ART [4]. ART
drastically improves survival and quality of life of HIV
patients [5–7], markedly declines AIDS progression, reduces
the incidence of infections and hospitalization, and decreases
the incidence of organ function complications [8, 9].
Although highly active antiretroviral therapy (HAART)
improved patients’ health outcome substantially, a significant
number of people on the first-line HAART failed to achieve
the required virological suppression [10]. As ART coverage
increased, simultaneously, it escalated resistance to ART
[11]. In Ethiopia, immunologic failure among pediatric
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patients was found to be 10% [12, 13]. Moreover, a study
conducted among adult HIV patients reported prevalence
of 22% from one study in the country [14]. In the southern
part of the country, an immunologic failure of 17.6% was also
detected [15]. Other studies from Bahirdar, Northwest
Ethiopia, Debremarkos, Northwest Ethiopia, and Gonder,
Northwest Ethiopia, found immunologic and clinical treat-
ment failures in 10.7%, 21%, and 4.1% of the studied patients,
respectively [16–18].
Failure to the first-line HAART regimen is perilous,
because the second-line HAART regimens are dearth and
unaffordable [19–24]. Recent estimates suggest that, although
2% of patients on ART are on a second-line regimen [25], a
number of patients are likely to be failed. Despite the failed
first-line HAART regimen, many patients have not been
switched to the second-line regimen [10]. A proportion of
HIV/AIDS patients who need the second-line and third-line
therapies continued to grow up with improvement in survival
of the patients. However, the second-line and third-line
HAART regimens are scarce which currently threaten
patients [26].
HIV/AIDS patients faced challenges when a patient had
stayed longer on the failed HAART regimen [24]. To over-
come the problem, guidelines have been developed by the
World Health Organization (WHO) to be implemented in
developing countries for patients on follow-up and to moni-
tor immunologic, clinical, and virologic response of patients
to their treatment [10]. Despite its importance, monitoring
virologic response of ART is a big challenge, specifically in
low-income nations. In developing countries like Ethiopia,
the detection, timely monitoring, and management of a
patient who failed his first-line regimen are compromised
and are also considered an immense problem [27, 28]. How-
ever, for resource-limited health care settings, the WHO
guideline has been developed and distributed parameters
for clinical and immunological monitoring of ART response
[29]. In Ethiopia, viral load testing is not available, unafford-
able, and not pragmatic as a routine practice in many health
care settings including the study area; instead, immunologi-
cal and clinical monitoring is routinely used. Treatment fail-
ure and its contributing factors in Ethiopia specifically in the
study area are not precisely known. This study, therefore,
investigated prevalence of clinical and immunologic failure
of people living with HIV after two years of ART use in
Northern Ethiopia.
2. Methods
2.1. Study Area. The study was conducted in the largest hos-
pital of Tigray region found in Mekelle city, which is named
Ayder Comprehensive Specialized Hospital (ACSH). Mekelle
is the capital city of Tigray region in Northern Ethiopia
which is located 783 km away from the capital of Ethiopia,
Addis Ababa. ACSH is a comprehensive specialized hospital
which serves a higher number of patients in the northern dis-
trict of the country. The hospital is a teaching as well as a
comprehensive specialized hospital. The hospital delivers
service for patients referred from Afar, Eritrean refuges and
referred patients, and patients from Amhara region in addi-
tion to the patients referred from various hospitals of the
region. The hospital has a HIV/AIDS clinic, which gives free
clinical service, counseling, and care for people living with
HIV/AIDS.
2.2. Study Design and Study Population. An institutional-
based cross-sectional study design was used to conduct the
study. People living with HIV who started HAART and
patients who were regularly followed at the HIV clinic of
ACSH were the source population in our study. Patients
who were registered at the ACSH HIV clinic and on follow-
up from 2009 to 2015 that fulfilled the inclusion criteria were
the study population. We included all HIV patients who had
regular follow-up at ACSH in the years between 2009 and
2015. On the other way, we excluded HIV patients who were
younger than 16 years, transferred outpatients, transferred
inpatients, HIV patients with incomplete data registry,
patients who were lost, patients who dropped from follow-
up, and HIV patients who had started HAART on 2016.
HIV patients were followed starting from the day of naïve
HAART initiation until the time of treatment failure or cen-
sor retrospectively. Survival time was measured in days from
the date of initiation of HAART until the time of treatment
failure/censor. HIV patients who had evidence of treatment
failure were declared to be failures and patients who did
not have treatment failure were considered censored. A total
of 770 out of 2134 patient registries of HIV patients who
started HAART from 2009 up to 2015 were included and
studied. The duration of the patients’ follow-up period was
2 consecutive years starting from the year of HAART
initiation.
Clinical and/or immunologic treatment failure was the
primary outcome of the study and was our dependent vari-
able. The WHO clinical and immunologic failure definition
was used by physicians in the HIV clinic to declare the treat-
ment failure. Based on the WHO guideline, treatment failure
was defined as the fall of CD4 count to baseline (or below),
CD4 levels persisting below 100 cells/mm, 50% fall from
the treatment peak value, or development of new opportunis-
tic infections [30]. Sex, place of residence, age, baseline
weight, baseline CD4 count, baseline TB symptoms, baseline
WHO stage, eligibility criteria, year of HAART initiation,
baseline functional status, and ART regimen were the inde-
pendent variables studied.
2.3. Data Collection Tool and Procedure. The Ethical Review
Board, College of Health Sciences, Mekelle University,
offered us an ethical clearance and approval of the study.
Informed written patient consent was obtained from patients
prior to data collection. Moreover, to obtain patients’ data,
permission was granted from the ACSH medical director
and HIV/AIDS clinic. We also confirm that all methods
were performed in accordance with the relevant guidelines
and regulations. The HIV/AIDS patients’ medical registry
review was entirely confidential. The standardized HIV
entry and follow-up form employed by the HIV clinic
was adapted and was used to extract data from patients’
medical registries. All the data was collected from the
patients’ medical registries, follow-up form, and patients’
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medical card. Two pharmacists who were working outside
the hospital were recruited, trained for two days, and col-
lected patients’ data. Prior to data collection, a pretest was
conducted on 39 patients. Patients who were involved in
the pretest assessment were excluded from data analysis.
Based on the pretest finding, amendments were done on
the data collection format. Close supervision and follow-
up on the data collection process were made by the prin-
cipal investigator.
2.4. Statistical Analysis. SPSS version 21 software was used
for data analysis. Data was refined and checked for consis-
tency and completeness. After the data was profoundly
assessed, the data was analyzed. Before data synthesis and
analysis, the data was entered and cleaned via the principal
investigator and one additional data clerk. Survival analy-
sis was deployed using the Kaplan-Meier model. The level
of significance of survival curves was compared through
Log-Rank (Mantel-Cox), Breslow (Generalized Wilcoxon),
and Tarone-W. Factors associated with treatment failure,
and its predictors were identified using Cox regression
proportional hazard model analysis. Meanwhile, the level
of significance was deemed to be significant at p value less
than 0.05.
3. Results
3.1. Demographic and Clinical Characteristics of Patients. A
total of 770 people who were living with HIV were analyzed.
Majority (442 (57.4%)) of the patients were females. The
average age of patients during initiation of ART was 32.9
± 9.5 [mean ± SD] years. On ART initiation, 410 (53.2%)
patients were WHO stage three (T3). Besides, TDF+3TC
+EFV was the most frequently prescribed HAART regimen
which was prescribed for 312 (40.5%) patients (Table 1).
3.2. Treatment Failure and Its Predictors. The median time to
ART failure was 15 months, whereas the mean (±SD) time to
fail the treatment was 13:11 ± 6:35 months. The prevalence
of treatment failure was calculated to be 4.5%. From the
35 patients who failed to treatment, 14 patients had
started TDF+3TC+EFV/NVP, thirteen patients started
AZT+3TC+NVP/EFV, and 8 patients had started D4T+
3TC+NVP/EFV regimens. Majority (34.3% (12)) of the
patients’ treatment failure occurred within 6 months, and
28.6% (10) of ART failure were detected after 21 months
of consecutive therapy. No record of treatment failure was
found within the 12th and 24th months of follow-up
(Figure 1).
All (100%) antiretroviral treatment failures were identi-
fied in the years 2009-2013. In 2014 and 2015, no evidence
of treatment failure was detected. Majority (1.8%) of the
treatment failures occurred in the years between 2010 and
2011, 0.5% in 2012, and 0.4% in 2009 (Figure 2).
The zidovudine-based regimen (Log-Rank (Mantel-Cox)
(p < 0:001)), baseline CD4 count (Log-Rank (Mantel-Cox)
(p = 0:012)), sex (Log-Rank (Mantel-Cox) (p = 0:004)), base-
line functional status (Log-Rank (Mantel-Cox) (p = 0:013)),
baseline WHO stage (Log-Rank (Mantel-Cox) (p = 0:004)),
and baseline TB symptoms (Log-Rank (Mantel-Cox)
(p = 0:001)) were variables that were significantly associated
with treatment failure.
The AZT-based regimen, baseline CD4 count, and base-
line functional status were the factors that were found to be
predictors of treatment failure on multivariate Cox regres-
sion analysis. Patients who started the zidovudine-based
regimen (AHR = 16:95, 95% CI: 3.02-95.1, p = 0:001) were
17 times more likely to have treatment failure than patients
who started the nonzidovudine-based ART regimen. Patients
with baseline CD4 count ≥ 301 cells/mm3 (AHR = 0:199,
95% CI: 0.05-0.76, p = 0:018) were 80% less likely to fail their
treatment than patients who had baseline CD4 count ≤ 200
cells/mm3. Moreover, patients who were bedridden at base-
line (AHR = 0:131, 95% CI: 0.029-0.596, p = 0:009) were
87% less likely to fail their therapy than patients who were
ambulatory during HAART initiation (Table 2).
Table 1: Demographic and clinical characteristics of HIV patients
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4. Discussion
Despite the significant change in the era of HIV management
from killer to a chronically manageable disease, another
problem, which is ART failure, began and continued to be
the hurdle for substantial control of the HIV/AIDS disease.
The extant of resistance HIV strains to the first-line ART reg-
imens leads patients to more expensive regimens and to use
medications that have less tolerable toxicities and are less
effective [20]. Treatment failure in combination with other
concomitant problems had remained the main challenge
for successful HIV treatment and milestone achievement
globally. It is vital to determine the prevalence of treatment
failure, identify factors that boost ART failure, and find out
strategies that could improve the problem quickly. In this
study, we mainly aimed to determine prevalence of treatment
failure in the specified setup. According to our calculation,
4.5% prevalence of antiretroviral treatment failure was dis-
cerned over the entire the 24-month follow-up period. With
regard to the factors of ART failure, patients who were on the
AZT-based regimen, baseline CD4 count, and baseline func-
tional status were the three predictors of treatment failure.
Our study found 4.5% prevalence of treatment failure
among the studied patients. This finding is quite lower when
compared to treatment failures reported in Gonder, Ethiopia
(11.5%) [14], Southwest Ethiopia (20.3%) [11], Northern
Ethiopia (22%) [13], Addis Ababa (8.2%) [11], and Western
Ethiopia (11.5%) [12]. The discrepancy could be due to the
differences of study population and follow-up periods. The
studies in Addis Ababa [11] and Jimma [12] were done
among children or people living with HIV. The studies also
had significant variation in methods of ART failure detection
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Figure 2: Distribution of treatment failure via the year of HAART initiation among people living with HIV in ACSH, Northern Ethiopia,
2017.
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used and length of follow-up periods [11–13]. Moreover, in
some sub-Saharan African countries, an overall higher
immunological failure that ranged from 10% to 32% was
reported in four studies [31, 32]. Furthermore, one study
from Nigeria reported an immunologic antiretroviral treat-
ment failure of 32% [33]. In addition to heterogeneity in
methodology, low detection skill of health care professionals
to identify treatment failure and lower patients’ registry doc-
umentation might contribute for lesser detection of treat-
ment failure in our study. In developing countries, many
patients died at their home and the patients who died at
home might not be documented in the patients’ chart
appropriately.
Patients who started the AZT-based regimen were 17
times more likely to develop treatment failure than patients
who started with the non-AZT-based regimen. This finding
concurred with other studies from Ethiopia. One study from
Ethiopia found higher risk of mortality with the AZT-based
HAART regimen as compared to the TDF-based regimen
[34]. Case-control studies done in Kenya also depicted that
ART clients who were taking the zidovudine-based regimen
experienced more treatment failures as compared to other
regimen-based treatments [35, 36]. In terms of virological
load suppression, both regimens had similar viral load sup-
pression [34]. On the contrary, immunological response
which was demonstrated in terms of the rise in CD4 count
was lowest in the AZT-based regimen as compared to the
TDF-based regimen [34]. Thus, the lower potential of the
CD4 count scale-up of the AZT-based regimen might lead
patients to develop opportunistic infections, which ulti-
mately insist declaration of immunologic antiretroviral treat-
ment failure [37]. The AZT-based regimen was the first-line
regimen before the TDF-based regimen was approved as
the first line. Besides utilization of AZT at higher levels in
the first 6 months of initiation, anemia and rash were the
most common reason accounting for treatment change in
many patients [38]. Therefore, drug toxicity might lead
patients to be nonadherent to their medication which could
lead them to treatment failure.
Patients who had baseline CD4 count ≥ 301cells/mm3
(AHR = 0:199, 95% CI: 0.05-0.76, p = 0:018) were 80% less
likely to fail their treatment than patients who had baseline
CD4 count ≤ 200 cells/mm3. There are studies that reported
that lower CD4 count has been associated with higher odds
of treatment failure [11, 39]. In low-income nations, use of
CD4 count was used for treatment decisions, for regimen
switch, and as a predictor of disease progression. It was
highly used as a criterion for HAART initiation and as a
marker of treatment outcomes [40]. CD4 count change after
the initiation of ART is known to be a good predictor of
Health-Related Quality of Life (HRQL) [41, 42]. CD4 count
also reduces risk of hospitalization prominently [38]. Thus,
patients who started at elevated CD4 count are less likely to
develop opportunistic infections, hence less likely to develop
clinical and immunologic failures.
Patients who were bedridden at the time of HAART ini-
tiation (AHR = 0:131, 95% CI: 0.029-0.596, p = 0:009) were
87% less likely to fail their treatment regimen than patients
who were ambulatory. Similar to this finding, studies from
the USA reported that advanced clinical stages predicted
improvement in CD4 count change. The lower risk of treat-
ment failure among bedridden patients could be due to better
care and ART adherence of the patients. When a patient has
poor adherence to antiretroviral therapy and cotrimoxazole
prophylaxis therapy, there will be a significant reduction in
CD4 count by 111.2 and 60.88 times, respectively, than good
adherence to ART and cotrimoxazole prophylaxis therapy
[42, 43]. Ergo, when a patient is adherent to his medication,
it will likely increase the CD4 count which would hinder
treatment failure on the other side [11].
Table 2: Predictors of treatment failure among people living with HIV in ACSH, Northern Ethiopia, 2017.
Variables
Treatment failure
AHR 95% CI p value
No (%) Yes (%)
ART regimen
Non-AZT-based 495 (67.3) 22 (62.9) 1 1 1
AZT-based 240 (32.7) 13 (371) 16.95 3.02-95.1 0.001∗
Baseline CD4 count
≤200 539 (73.3) 26 (74.3) 1 1 1
200-300 124 (16.9) 3 (8.6) 1.25 0.26-6.02 0.781
≥301 72 (9.8) 6 (17.1) 0.199 0.05-0.76 0.018∗
Sex
Female 422 (57.4) 20 (57.1) 1 1 1
Male 313 (42.6) 15 (42.9) 0.622 0.27-1.45 0.272
Baseline functional status
Ambulatory 185 (25.2) 18 (51.4) 1 1 1
Working 474 (64.5) 13 (37.1) 1.04 0.29-3.47 0.995
Bedridden 76 (10.3) 4 (11.4) 0.131 0.029-0.596 0.009∗
Baseline WHO stage
T1 and T2 208 (28.3) 2 (5.7) 1 1 1
T3 391 (53.2) 19 (54.3) 0.915 0.155-5.4 0.922
T4 136 (18.5) 14 (40) 3.4 0.42-27.52 0.251
Note: AHR: adjusted hazard ratio; CI: confidence interval; ART: antiretroviral therapy; WHO: World Health Organization; AZT: zidovudine. ∗Statistical
significance at p < 0:05.
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Our study is not without flaw; hence, it has some limita-
tions. We used the patients’ registry as our main source of
data. Therefore, both the ART database and ART patients’
chart are the secondary sources; thus, all the problems related
to the use of the secondary data apply to this study. More-
over, some important predictors like CPT adherence and
AST and ALT levels due to poor patient medical card docu-
mentation were not collected. Despite some limitations, this
study included a representative number of patients to eluci-
date the issue.
5. Conclusion
The prevalence of treatment failure was significantly lower
when compared to many local and global studies. High risk
of treatment failure was found among patients on the
AZT-based regimen. Low risk of treatment failure was found
among patients who started HAART at baseline CD4 count
≥ 301. Moreover, patients who were bedridden during initi-
ation of HAART were less likely to develop treatment failure.
To precisely detect the prevalence of treatment failure which
could be generalized to general population, a prospective
cohort multicenter study is recommended.
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